M. Keskinkılıç

发表

CD47 (don't eat me signal) expression levels and its relationship with clinicopathologic features in early‐stage prostate carcinoma

H. Semiz, Ü. Küçük, Mehmet Emin Arayici, 2022, The Prostate.

Approach to the Treatment of Metastatic Castration-Sensitive Prostate Carcinoma: A Single Center Experience

H. Semiz, Mehmet Emin Arayici, Halil İbrahim Ellez, 2022, Journal of Basic and Clinical Health Sciences.

Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study

Ö. Acar, A. Erdoğan, S. Kılıçkap, 2022, Breast.

Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study.

D. Erdem, B. Öksüzoğlu, D. Aydın, 2022, Future oncology.

Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer.

U. Demirci, Ozlem Dogan, A. Erdoğan, 2023, Future oncology.

The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

D. Erdem, D. Aydın, B. Yalcin, 2022, Journal of Cancer Research and Clinical Oncology.

The prognostic indicator in breast cancer treated with CDK4/6 inhibitors: the prognostic nutritional index.

I. Oztop, T. Yavuzşen, H. Semiz, 2023, Future oncology.

The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and endocrine therapy: A multicentric retrospective study

T. Yavuzşen, M. Keser, M. Sari, 2023, Breast.

CDK4/6 Inhibition in the Metastatic Setting: Where Are We Headed?

K. Kalinsky, Elizabeth Sakach, M. Keskinkılıç, 2023, Current Treatment Options in Oncology.

The Prognostic Nutritional Index (PNI): A New Biomarker for Determining Prognosis in Metastatic Castration-Sensitive Prostate Carcinoma

I. Oztop, H. Semiz, Erdem Kısa, 2023, Journal of clinical medicine.

The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

D. Erdem, D. Aydın, B. Yalcin, 2022, Journal of Cancer Research and Clinical Oncology.

Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Ö. Acar, A. Erdoğan, Kubilay Karaboyun, 2023, BMC Cancer.

Is the percentage of hormone receptor positivity in HR+ HER2-metastatic breast cancer patients receiving CDK 4/6 inhibitor with endocrine therapy predictive and prognostic?

T. Yavuzşen, M. Keskinkılıç, Hüseyin Salih Semiz, 2024, Frontiers in Oncology.

The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study.

A. Erdoğan, S. Kılıçkap, B. Çakar, 2024, International journal of clinical oncology.

The Evaluation of Pazopanib Treatment Experience and Real-Life Data in Metastatic Soft Tissue Sarcoma

M. Keskinkılıç, Merve Keskinkilic, 2023, Eurasian Journal of Medical Investigation.